GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

GAZYVA + bendamustine followed by GAZYVA monotherapy provided superior PFS vs bendamustine alone 1

GAZYVA GADOLIN Primary Endpoint: IRC-assessed PFS Chart